AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1468089 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily
Number of subjects: 544
Study 1468089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg once daily
Number of subjects: 544
Study 1468089 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 544
Study 1468089 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 40 mg
Number of subjects: 544
Study 1468089 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 544
Study 1468089 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients
Number of subjects: 544
Study 6242074 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 20
Study 6242074 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline
Number of subjects: 20
Study 31309775 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ILO once monthly
Number of subjects: 96
Study 31309775 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ILO for 5 consecutive days every 3 months
Number of subjects: 96
Study 31309775 — intervention group
Group type: COMPARATOR
Intervention: Not requiring therapy with IV ILO
Number of subjects: 96
Study 30249366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg once a day
Number of subjects: 0
Study 30249366 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg BID
Number of subjects: 0
Study 30249366 — intervention group
Group type: COMPARATOR
Intervention: Gemigliptin + Metformin
Number of subjects: 0
Study 30249366 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Number of subjects: 0
Study 27658839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy (including EMDR)
Number of subjects: 38
Study 27658839 — intervention group
Group type: COMPARATOR
Intervention: Outpatient clinical management (control group)
Number of subjects: 38
Study 27658839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient psychotherapy
Number of subjects: 38
Study 25234012 — intervention group
Group type: EXPERIMENTAL
Intervention: Part-time patching for 3 hours daily for 5 months
Number of subjects: 358
Study 25234012 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment for 6 months)
Number of subjects: 358
Study 22914450 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling to 33.5 °C for 72 hours
Number of subjects: 208
Study 22914450 — intervention group
Group type: COMPARATOR
Intervention: Outborn infants (n = 93)
Number of subjects: 208
Study 22914450 — intervention group
Group type: COMPARATOR
Intervention: Inborn infants (n = 115)
Number of subjects: 208
Study 20230254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 200 mg
Number of subjects: 12
Study 20230254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 300 mg
Number of subjects: 12
Study 20230254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride 400 mg
Number of subjects: 12
Study 17266089 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) with intraarticular methylprednisolone injections
Number of subjects: 59
Study 17266089 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT) with nonsteroidal antiinflammatory drugs
Number of subjects: 59
Study 17266089 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) with sulfasalazine
Number of subjects: 59
Study 17266089 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT) with sulfasalazine
Number of subjects: 59
Study 16186417 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 30
Study 16186417 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 11863285 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide extraction method using solid-phase extraction and liquid chromatography-tandem mass spectrometry
Number of subjects: 0
Study 10522120 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised templates for asthma and diabetes management
Number of subjects: 6
Study 10522120 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment through semi-structured interviews
Number of subjects: 6
Study 10522120 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessment through change in use of the template
Number of subjects: 6
Study 7717632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Number of subjects: 0
Study 1851183 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (0.5 micrograms/kg)
Number of subjects: 5
Study 1851183 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (1 microgram/kg)
Number of subjects: 5
Study 1851183 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (2 micrograms/kg)
Number of subjects: 5
Study 1851183 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 5
Study 7010014 — intervention group
Group type: EXPERIMENTAL
Intervention: Family care
Number of subjects: 0
Study 7010014 — intervention group
Group type: COMPARATOR
Intervention: Child-only care
Number of subjects: 0
Study 31518174 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + OFS (5 years of Tamoxifen with 2 years of ovarian function suppression using monthly goserelin administration)
Number of subjects: 1483
Study 31518174 — intervention group
Group type: COMPARATOR
Intervention: TAM-Only (5 years of Tamoxifen)
Number of subjects: 1483
Study 31596369 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative (FBF)
Number of subjects: 54
Study 31596369 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma Smart Composite (CSC)
Number of subjects: 54
Study 31596369 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia Forte Fil (EF)
Number of subjects: 54
Study 28698350 — intervention group
Group type: EXPERIMENTAL
Intervention: nanocurcumin (40 mg capsules, 2 per day for 3 months)
Number of subjects: 84
Study 28698350 — intervention group
Group type: COMPARATOR
Intervention: placebo (40 mg capsules, 2 per day for 3 months)
Number of subjects: 84
Study 26191648 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA-SGD
Number of subjects: 3
Study 26191648 — intervention group
Group type: COMPARATOR
Intervention: AMA-N
Number of subjects: 3
Study 26191648 — intervention group
Group type: COMPARATOR
Intervention: Y-SGD
Number of subjects: 3
Study 23381521 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced support for shared decision making
Number of subjects: 0
Study 23381521 — intervention group
Group type: COMPARATOR
Intervention: Usual level of support
Number of subjects: 0
Study 22616228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic preconditioning (HP) during CABG, one cycle of 10-minute hypoxemia followed by a 5-minute reoxygenation.
Number of subjects: 47
Study 22616228 — intervention group
Group type: COMPARATOR
Intervention: No renal protection (comparison group).
Number of subjects: 47
Study 20368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar 2.5 mg
Number of subjects: 583
Study 20368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar 5 mg
Number of subjects: 583
Study 20368202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide plus muraglitazar (both doses)
Number of subjects: 583
Study 20368202 — intervention group
Group type: COMPARATOR
Intervention: Glyburide plus placebo
Number of subjects: 583
Study 17473298 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan
Number of subjects: 1327
Study 17473298 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dobutamine
Number of subjects: 1327
Study 15367726 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (800 mg)
Number of subjects: 10
Study 15367726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1200 mg)
Number of subjects: 10
Study 15367726 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (1500 mg)
Number of subjects: 10
Study 15367726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11740041 — intervention group
Group type: EXPERIMENTAL
Intervention: Health message focusing on smokers' sensory perceptions of Light and Ultra Light cigarettes
Number of subjects: 2120
Study 11740041 — intervention group
Group type: COMPARATOR
Intervention: Health message focusing on vent holes
Number of subjects: 2120
Study 11740041 — intervention group
Group type: COMPARATOR
Intervention: Health message focusing on health consequences of smoking
Number of subjects: 2120
Study 11541259 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic-optokinetic stimulus (HOS)
Number of subjects: 20
Study 11541259 — intervention group
Group type: COMPARATOR
Intervention: Optokinetic stimulus (OS)
Number of subjects: 20
Study 8177898 — intervention group
Group type: EXPERIMENTAL
Intervention: Support offered by a nurse practitioner
Number of subjects: 0
Study 2439977 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary infant development program (IDP)
Number of subjects: 0
Study 2439977 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (control group)
Number of subjects: 0
Study 29351799 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet plus extravirgin OO, 20-30 g/day
Number of subjects: 180
Study 29351799 — intervention group
Group type: COMPARATOR
Intervention: Control MedDiet
Number of subjects: 180
Study 29351799 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet plus extravirgin OO
Number of subjects: 180
Study 25946163 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and Conditioning (S&C) group (n = 8)
Number of subjects: 16
Study 25946163 — intervention group
Group type: COMPARATOR
Intervention: Endurance-Only (EO) group (n = 8)
Number of subjects: 16
Study 25605469 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO-derived physiological values
Number of subjects: 350
Study 25605469 — intervention group
Group type: COMPARATOR
Intervention: Control group (CVP monitoring)
Number of subjects: 350
Study 23658161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibition
Number of subjects: 0
Study 23658161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20060517 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 20
Study 20060517 — intervention group
Group type: COMPARATOR
Intervention: Applied Relaxation (AR)
Number of subjects: 20
Study 17851756 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestive therapy
Number of subjects: 408
Study 17851756 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 408
Study 16739389 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing modes that maintain atrioventricular synchrony
Number of subjects: 0
Study 16739389 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization with specialized left ventricular leads
Number of subjects: 0
Study 14622084 — intervention group
Group type: EXPERIMENTAL
Intervention: sibutramine
Number of subjects: 53
Study 14622084 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing participants about realistic weight loss expectations (5% to 15%)
Number of subjects: 53
Study 11157559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with eyes open, feet together
Number of subjects: 6
Study 11157559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with eyes closed, feet together
Number of subjects: 6
Study 11157559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with eyes closed
Number of subjects: 6
Study 11157559 — intervention group
Group type: COMPARATOR
Intervention: Standing with eyes open or closed, feet together or apart
Number of subjects: 6
Study 11157559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing with eyes closed or feet together
Number of subjects: 6
Study 11157559 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing
Number of subjects: 6
Study 9469128 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen in the snoezelen room
Number of subjects: 17
Study 9469128 — intervention group
Group type: COMPARATOR
Intervention: Living room (control)
Number of subjects: 17
Study 7938858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal puncture and anesthesia with 2.5 mg/kg bupivacaine 1:200,000
Number of subjects: 140
Study 7938858 — intervention group
Group type: COMPARATOR
Intervention: Lumbar puncture at L4‐L5 and 1.25 mg/kg of bupivacaine
Number of subjects: 140
Study 7938858 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter in the caudal space up to L4‐L5 and 1.25 mg/kg of bupivacaine administered through the catheter
Number of subjects: 140
Study 7938858 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural catheter in the caudal space up to L4‐L5
Number of subjects: 140
Study 7938858 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 140
Study 7938858 — intervention group
Group type: COMPARATOR
Intervention: Groups 1 and 2
Number of subjects: 140
Study 7938858 — intervention group
Group type: COMPARATOR
Intervention: Group 3
Number of subjects: 140
Study 2836324 — intervention group
Group type: EXPERIMENTAL
Intervention: Imuthiol (Na diethyldithiocarbamate) adjuvant therapy
Number of subjects: 0
Study 2836324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2836324 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients vaccinated annually for several years)
Number of subjects: 0
Study 30998526 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 0
Study 30998526 — intervention group
Group type: COMPARATOR
Intervention: Leaflets
Number of subjects: 0
Study 28664763 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief compassion focused imagery (CFI)
Number of subjects: 0
Study 28664763 — intervention group
Group type: COMPARATOR
Intervention: Relaxation imagery (RI)
Number of subjects: 0
Study 28664763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CFI and RI
Number of subjects: 0
Study 28353023 — intervention group
Group type: EXPERIMENTAL
Intervention: GUM Hydral mouthwash plus gel
Number of subjects: 40
Study 28353023 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotene Oralbalance mouthwash plus gel
Number of subjects: 40
Study 28353023 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 26153784 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS
Number of subjects: 113
Study 26153784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 26153784 — intervention group
Group type: COMPARATOR
Intervention: Term control group
Number of subjects: 113
Study 26153784 — intervention group
Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS/pAOS and Placebo
Number of subjects: 113
Study 23550740 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam TMOS
Number of subjects: 280
Study 23550740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 21467028 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 302
Study 21467028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 17963805 — intervention group
Group type: EXPERIMENTAL
Intervention: SSG+Alum/ALM+BCG
Number of subjects: 30
Study 17963805 — intervention group
Group type: COMPARATOR
Intervention: SSG alone
Number of subjects: 30
Study 17963805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 16536204 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination of the adhesive surface with fresh saliva before light curing (A) - A1 subgroup: Saliva removed by gentle air blast; A2 subgroup: Saliva rinsed for 10 seconds, air-dried; A3 subgroup: Saliva rinsed, dried, adhesive re-applied.
Number of subjects: 0
Study 16536204 — intervention group
Group type: EXPERIMENTAL
Intervention: Contamination of the adhesive surface with fresh saliva after light curing (B) - B1 subgroup: Saliva removed with gentle air blast; B2 subgroup: Saliva rinsed and dried; B3 subgroup: Saliva rinsed, dried, adhesive re-applied.
Number of subjects: 0
Study 16536204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contamination)
Number of subjects: 0
Study 16536204 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III - A1 subgroup
Number of subjects: 0
Study 12752890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous conjugated equine oestrogen (25 mg)
Number of subjects: 20
Study 12752890 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 11082823 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transdermal nicotine patch
Number of subjects: 30
Study 11082823 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 30
Study 9337508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 112
Study 9337508 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic-interpersonal therapy
Number of subjects: 112
Study 8402805 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.12%, Peridex)
Number of subjects: 0
Study 8402805 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc and triclosan (high humectant)
Number of subjects: 0
Study 8402805 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 0
Study 30968140 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate high-fat breakfast (LCBF; <10% of energy from carbohydrate, 85% of energy from fat, 15% of energy from protein)
Number of subjects: 23
Study 30968140 — intervention group
Group type: COMPARATOR
Intervention: Dietary guidelines‐recommended nutrient profile breakfast (GLBF; 55% of energy from carbohydrate, 30% of energy from fat, 15% of energy from protein)
Number of subjects: 23
Study 29178730 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% potassium nitrate and 2% sodium fluoride
Number of subjects: 60
Study 29178730 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% strontium chloride
Number of subjects: 60
Study 29178730 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with 22% carbamide peroxide followed by a toothpaste without active ingredient
Number of subjects: 60
Study 25616881 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 6.25 mg IV
Number of subjects: 120
Study 25616881 — intervention group
Group type: COMPARATOR
Intervention: Promethazine 12.5 mg IV
Number of subjects: 120
Study 23255569 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet (LGD)
Number of subjects: 113
Study 23255569 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 113
Study 23255569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LGD and LFD
Number of subjects: 113
Study 20940182 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 30
Study 20940182 — intervention group
Group type: COMPARATOR
Intervention: Control group (bowel management advice only)
Number of subjects: 30
Study 18279487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 3 mg x kg(‐1)
Number of subjects: 60
Study 18279487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16006428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g/d)
Number of subjects: 100
Study 16006428 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 100
Study 12598354 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine with montanide ISA 51 as adjuvant
Number of subjects: 40
Study 12598354 — intervention group
Group type: COMPARATOR
Intervention: EGF vaccine with aluminum hydroxide as adjuvant
Number of subjects: 40
Study 12598354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide prevaccination treatment
Number of subjects: 40
Study 12598354 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF vaccine (five doses)
Number of subjects: 40
Study 9890172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine treatment (intravenous on days 1 and 8 of a 21-day cycle for six cycles)
Number of subjects: 161
Study 9890172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine treatment
Number of subjects: 161
Study 9890172 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (Control)
Number of subjects: 161
Study 15374185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergokryptine (DEK) 5 mg bid for 2 weeks, 10 mg bid for 2 weeks, 20 mg bid for 11 months
Number of subjects: 215
Study 15374185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 1856491 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) at doses of 0.1, 0.25 mg/kg; 0.5 mg/kg not given to AB group.
Number of subjects: 16
Study 1856491 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B desoxycholate (AB) at doses of 0.1, 0.25 mg/kg.
Number of subjects: 16
Study 1856491 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC)
Number of subjects: 16
Study 1856491 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B desoxycholate (AB)
Number of subjects: 16
Study 6348630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% with epinephrine and/or hyaluronidase
Number of subjects: 111
Study 6348630 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine and hyaluronidase
Number of subjects: 111
Study 30987662 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy (CMT)
Number of subjects: 60
Study 30987662 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 60
Study 30987662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CMT + UC)
Number of subjects: 60
Study 29548298 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback during exposure
Number of subjects: 80
Study 29548298 — intervention group
Group type: COMPARATOR
Intervention: Motor pseudo-biofeedback task during exposure
Number of subjects: 80
Study 29548298 — intervention group
Group type: COMPARATOR
Intervention: Two pseudo-biofeedback tasks during exposure
Number of subjects: 80
Study 29548298 — intervention group
Group type: COMPARATOR
Intervention: No additional task during exposure
Number of subjects: 80
Study 26801468 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of iPad Airs for administering the Whooley questions and the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 0